RxDoctor Payments Data

Farhan Siddiqui, MD

Internal Medicine · Macon, GANPI 1598754301

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 100.0% of the total across 37 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 16 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $221 and has fallen 71.3% since, to $63 in 2025.

$577in general payments, 2019–2025

Across 37 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$120
  • Melinta Therapeutics, LLC$68
  • Cumberland Pharmaceuticals, Inc.$55
  • Johnson & Johnson$47
  • Kerecis Limited$46
  • Actelion Pharmaceuticals US, Inc.$42
  • plus $199 from 10 others
$2,677in research payments, 2019–2025

Across 5 payments — averaging $535.31 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$3K

What the payments were for

  • Food & beverage$577100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$577 in reported general payments places this provider in the 60th percentile of 3,311 internal medicine providers in Georgia.

See all internal medicine providers in Georgia →

Medicare billing

Part B allowed, 2024
$697,959
Medicare patients
591
Services billed
7,791

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Daptomycin191$211,633
Vancomycin Hcl187$35,722
Meropenem90$22,430
CeftriaxoneCeftriaxone Sodium122$21,903
Cefepime Hcl120$16,075
ErtapenemErtapenem Sodium39$15,017
MicafunginMicafungin Sodium48$14,970
Ampicillin Sodium16$4,430
Piperacillin-TazobactamPiperacillin Sodium/Tazobactam16$3,559
Sodium Chloride0.9 % Sodium Chloride11$2,124
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav66$1,067
Doxycycline Monohydrate49$668
Metronidazole37$628
Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim74$478
Doxycycline Hyclate42$450

Paid to pharmacies, not to this prescriber.

Other internal medicine in Macon

See the full list for Georgia →

Where these figures come from

Is this you, or does something look wrong? →